What one share of Phathom Pharmaceuticals holds
We are a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA®, VOQUEZNA® DUAL PAK® and VOQUEZNA® TRIPLE PAK®, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB.
Phathom Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.06 |
|---|---|
| Profit | −$1.27 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.47 |
| Cash and investments | $2.28 |
| Debt | $2.06 |
| Book value | −$4.30 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$0.21 | — | — | — | −$0.19 |
| 2019 | — | −$22.45 | $0.01 | −$3.22 | — | — |
| 2020 | — | −$3.88 | $0.03 | −$2.13 | — | $6.81 |
| 2021 | — | −$3.89 | $0.01 | −$4.02 | — | $2.36 |
| 2022 | $0.00 | −$5.05 | $0.03 | −$3.77 | — | −$1.80 |
| 2023 | $0.01 | −$3.93 | $0.03 | −$2.71 | — | −$1.26 |
| 2024 | $0.87 | −$5.29 | $0.00 | −$4.22 | — | −$3.70 |
| 2025 | $2.40 | −$3.03 | $0.00 | −$2.29 | — | −$6.14 |
Common questions about Phathom Pharmaceuticals
How much does one share of Phathom Pharmaceuticals earn?
Over the last 12 months, Phathom Pharmaceuticals lost $1.27 for each share on $3.06 of sales.
Does Phathom Pharmaceuticals pay a dividend?
Phathom Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Phathom Pharmaceuticals’s book value per share?
Phathom Pharmaceuticals’s book value is negative (−$4.30 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Phathom Pharmaceuticals have?
Each share of Phathom Pharmaceuticals has $2.28 of cash and investments and $2.06 of debt, as of June 30, 2026.
What is Phathom Pharmaceuticals’s free cash flow per share?
−$0.47 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Phathom Pharmaceuticals bought back shares?
Phathom Pharmaceuticals’s share count rose about 1105% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.